Based on the key indicators related to Allogene Therapeutics' liquidity, profitability, solvency, and operating efficiency, Allogene Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Allogene Therapeutics' Short Term Investments are very stable compared to the past year. As of the 20th of March 2025, Net Invested Capital is likely to grow to about 677.7 M, while Other Current Liabilities is likely to drop about 28.3 M. Key indicators impacting Allogene Therapeutics' financial strength include:
Investors should never underestimate Allogene Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Allogene Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Allogene Therapeutics.
Net Income
(270.47 Million)
Allogene
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Investments
Change In Cash
Total Cashflows From Investing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Change To Netincome
Change To Liabilities
Sale Purchase Of Stock
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
End Period Cash Flow
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Net Invested Capital
Long Term Investments
Total Current Assets
Net Working Capital
Common Stock
Short Long Term Debt Total
Other Liab
Property Plant And Equipment Net
Net Debt
Other Assets
Cash And Short Term Investments
Net Receivables
Retained Earnings Total Equity
Liabilities And Stockholders Equity
Capital Surpluse
Capital Lease Obligations
Inventory
Other Current Assets
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Capital Stock
Non Current Liabilities Other
Property Plant Equipment
Current Deferred Revenue
Short Term Debt
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Other Operating Expenses
Ebitda
Reconciled Depreciation
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Allogene Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Allogene Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Allogene Therapeutics' assets may result in an increase in income on the income statement.
Allogene Therapeutics competes with Heron Therapeuti, Annexon, Sangamo Therapeutics, Beam Therapeutics, and Sana Biotechnology. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 344 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Allogene Therapeutics's current stock value. Our valuation model uses many indicators to compare Allogene Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Allogene Therapeutics competition to find correlations between indicators driving Allogene Therapeutics's intrinsic value. More Info.
Allogene Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Allogene Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Allogene Therapeutics' earnings, one of the primary drivers of an investment's value.
Allogene Therapeutics Systematic Risk
Allogene Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Allogene Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Allogene Therapeutics correlated with the market. If Beta is less than 0 Allogene Therapeutics generally moves in the opposite direction as compared to the market. If Allogene Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Allogene Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Allogene Therapeutics is generally in the same direction as the market. If Beta > 1 Allogene Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Allogene Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Allogene Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Allogene Therapeutics growth as a starting point in their analysis.
Allogene Therapeutics March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Allogene Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Allogene Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Allogene Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Allogene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Allogene Therapeutics's daily price indicators and compare them against related drivers.
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.32)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.27)
Return On Equity
(0.55)
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.